Remove Clinical Trials Remove Concentrates Remove Pharmaceutical Remove Topical
article thumbnail

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

Cannabis Law Report

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

‘Junk’ cannabis ‘ill-suited for clinical trials’. The cannabis grown at the University of Mississippi “is junk, ill-suited for clinical trials, and genetically closer to hemp than the marijuana available from dispensaries and used by Americans nationwide,” according to the lawsuit. Shutterstock).

DEA 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Cannabis Law Report

.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. The maximum plasma concentration (Cmax) was reached at 4 hours post-dose, and plasma Epoladerm remained at 24-hour post-dose for all animals. About Virpax Pharmaceuticals. Mack, Chairman and CEO of Virpax. Forward-Looking Statement.

article thumbnail

Heritage Cannabis Provides Update on Growth of Canadian Recreational Division and Launch of CB4 Branded Medical Products in Canada

Cannabis Law Report

In Ontario, Heritage achieved fastest growing concentrate sales and grew to #5 and #6 in sales in the concentrate category within one month of launching in the province. of the market share in the concentrates category, and RAD alone grew from 7.5% Sales of vape products in Q3 increased 119% quarter-over-quarter in the B.C.

article thumbnail

World Respiratory Health Management Technology Market Report 2021 Featuring Clin-e-cal, Cognita Labs, Qure AI, ResApp Health Limited, & Zebra Medical Vision – ResearchAndMarkets.com

Cannabis Law Report

Technology licensing should be on the radar for pharmaceutical companies offering drugs for respiratory diseases. Key Topics Covered: 1.0 Improving Patient Outcomes with Real-time Feedback via Smart Inhalers and Portable and Lightweight Oxygen Concentrators for Increasing Home-Based Therapy is a Key Growth Opportunity.

article thumbnail

Medical marijuana can be used to treat Depression

FloridaMarijuana.net

Decreased energy, fatigue, feeling “slowed down” Difficulty concentrating, remembering, making decisions. Some patients find success with pharmaceuticals and talk-therapy. In addition to these medical interventions, Medical marijuana may also be beneficial to clinically depressed patients.

Marijuana 189
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.